The Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) phase 2b trial evaluated Finerenone’s safety and efficacy in 823 patients with T2DM and albuminuric CKD [28]. This evidence concerns the gene NR3C2 and chronic kidney disease.